Richard Shlofmitz, MD
Interventional Cardiology · Roslyn, NYNPI 1730192709
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,875 of the $52,913 with a category attached, or 81.0%. Shockwave Medical, Inc accounts for 83.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $42,472 and has fallen 98.0% since, to $867 in 2025.
Across 139 payments — averaging $380.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$44K
- Abbott$4K
- Abiomed$2K
- Spectrawave, Inc$518
- Medtronic$428
- Johnson & Johnson$375
- plus $2K from 20 others
Across 408 payments — averaging $10,860 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$2M
- Boston Scientific$815K
- Shockwave Medical, Inc$791K
- Philips North America LLC$371K
- Cardiovascular Systems Inc.$353K
- Magenta Medical Inc$109K
- plus $29K from 1 others
What the payments were for
- Consulting fees$42,87581%
- Speaking & faculty fees$2,5005%
- Travel & lodging$1,3723%
- Food & beverage$6,16512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 23 | $44,235 |
| Abbott | 72 | $3,847 |
| Abiomed | 2 | $1,883 |
| Spectrawave, Inc | 2 | $518 |
| Medtronic(2 entities) | 6 | $428 |
| Johnson & Johnson | 3 | $375 |
| Cathworks, Inc. | 1 | $200 |
| Cardiva Medical, Inc. | 7 | $145 |
| Boston Scientific | 2 | $140 |
| Siemens Medical Solutions USA, Inc. | 1 | $139 |
| Amgen | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Acist Medical Systems, Inc. | 1 | $124 |
| Arrow International, Inc. | 1 | $118 |
| Biohaven Pharmaceuticals, Inc. | 1 | $88 |
| Esperion Therapeutics, Inc. | 4 | $72 |
| Philips North America LLC | 1 | $45 |
| Impulse Dynamics (USA) Inc. | 2 | $38 |
| Kestra Medical Technology Services, Inc. | 1 | $31 |
| GE HealthCare | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Penumbra, Inc. | 1 | $17 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascular Lithotripsy$43,135
- Impella$1,883
- Xience V coronary stent system$1,371
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$888
- HyperVue Imaging System$518
- XARELTO$375
- OPTIS$296
- FFRangio$200
- Resolute$151
- XIENCE V$133
- Ultreon$133
- JARDIANCE$125
- Repatha$125
- Wegovy$125
- CVI SYSTEMS$124
- TURNPIKE CATHETER$118
- Dragonfly OCT$103
How this compares
$52,913 in reported general payments places this provider in the 80th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 420 | $526,360 |
| EliquisApixaban | 369 | $479,894 |
| Repatha SureclickEvolocumab | 263 | $226,165 |
| EntrestoSacubitril/Valsartan | 165 | $201,614 |
| MultaqDronedarone Hcl | 62 | $118,490 |
| Praluent PenAlirocumab | 130 | $87,527 |
| BrilintaTicagrelor | 37 | $37,291 |
| Prasugrel Hcl | 464 | $35,458 |
| JardianceEmpagliflozin | 26 | $32,880 |
| Metoprolol Succinate | 1,148 | $19,064 |
| OzempicSemaglutide | 18 | $17,329 |
| FarxigaDapagliflozin Propanediol | 14 | $16,374 |
| Ranolazine ErRanolazine | 143 | $14,436 |
| Rosuvastatin Calcium | 870 | $13,494 |
| Valsartan | 446 | $13,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $375 | $526,360420 claims |
| PfizerEliquis | $11 | $479,894369 claims |
| Boehringer IngelheimJardiance | $125 | $32,88026 claims |
| Novo NordiskOzempic | $125 | $17,32918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Roslyn
- Evan ShlofmitzRoslyn$951K
- David CohenRoslyn$392K
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.